Preclinical Ketamine Trial Shows Positive Results For Pain Conditions Like Fibromyalgia And Arthritis

Biotech psychedelics researcher and developer Silo Pharma Inc. (OTCQB: SILO) announced its topically-administered proprietary ketamine obtained a positive outcome in a recent preclinical study.

The trial has then proven the combination of Silo’s ketamine together with Zylo’s delivery system to yield positive results in reducing neuropathic nerve pain in a small animal study.

This data is extremely promising for patients suffering from fibromyalgia and rheumatoid arthritis,” CEO Eric Weisblum said.

“These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. "

More …

Full story available on Benzinga.com

Preclinical Ketamine Trial Shows Positive Results For Pain Conditions Like Fibromyalgia And Arthritis on Benzinga